[1]周杰 朱遵伟** 曾涛 贾灵华 毛允义 王金根.维持性血液透析患者后腹腔镜肾癌根治术的安全性[J].中国微创外科杂志,2020,01(3):274-277.
　Zhou Jie,Zhu Zunwei,Zeng Tao,et al.On Safety of Retroperitoneoscopy in Maintenance Hemodialysis Patients With Renal Cell Carcinoma[J].Chinese Journal of Minimally Invasive Surgery,2020,01(3):274-277.
点击复制

维持性血液透析患者后腹腔镜肾癌根治术的安全性()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
01
期数:
2020年3期
页码:
274-277
栏目:
经验交流
出版日期:
2020-03-25

文章信息/Info

Title:
On Safety of Retroperitoneoscopy in Maintenance Hemodialysis Patients With Renal Cell Carcinoma
作者:
周杰 朱遵伟** 曾涛 贾灵华 毛允义 王金根
（江西省人民医院泌尿外科，南昌330006）
Author(s):
Zhou Jie;  Zhu Zunwei;  Zeng Tao;  et al.
Department of Urology, Jiangxi Provincial People’s Hospital, Nanchang 330006, China
关键词:
肾细胞癌; 血液透析; 根治性肾切除术; 后腹腔镜
Keywords:
Renal cell carcinoma; Hemodialysis; Radical nephrectomy; Retroperitoneal laparoscopy
文献标志码:
B
摘要:
目的探讨后腹腔镜根治性肾切除术治疗维持性血液透析合并肾癌患者的安全性。方法回顾性分析我院2013年1月~2019年3月9例终末期肾病（维持性血液透析）合并肾癌患者的临床资料。肿瘤最大径平均3.7 cm（1.2~5.4 cm），临床分期T1N0M0。维持性血液透析时间19~62个月，平均50个月。均行后腹腔镜根治性肾切除术。术前改善全身一般状况并加强血液透析，围手术期予普通血液透析和无肝素血液透析相结合的方法行肾脏替代治疗，术中、术后限制性补液。结果9例手术均顺利完成，无中转开放、术中输血及死亡。手术时间67~160 min，平均102.9 min。术中出血量40~120 ml，平均73.3 ml。术后第1天即行无肝素血液透析，恢复普通血液透析时间6~7 d。术后急性左心衰竭1例，皮下气肿1例，均对症治愈。术后住院时间7~12 d，平均8.1 d。术后随访5~70个月，平均35个月，均存活，未见肿瘤复发及远处转移，继续血液透析。结论只要术前准备充分，围手术期周密管理，加之个体化补液和及时血液透析，维持性血液透析患者并发肾癌行后腹腔镜手术安全有效。
Abstract:
ObjectiveTo explore the safety of retroperitoneal laparoscopic radical nephrectomy (RLRN) for renal cell carcinoma (RCC) in maintenance hemodialysis patients.MethodsThe clinical data of 9 patients with endstage renal diseases (ESRD) who underwent maintenance hemodialysis complicated with nonmetastatic RCC diagnosed in our hospital from January 2013 to March 2019 were retrospectively analyzed. The mean largest dimension of the tumor was 3.7 cm, ranging from 1.2 to 5.4 cm. The clinical stage of the tumors was T1N0M0. The mean duration of dialysis before diagnosis of RCC was 50 months, ranging from 19 to 62 months. All the patients underwent the RLRN. The general condition of patients was improved and hemodialysis was strengthened before operation. The perioperative renal replacement treatment was regular hemodialysis combined with nonheparin hemodialysis. Fluid infusion was restricted during and after operation.ResultsAll the operations were completed successfully without conversion to open surgery. No mortality was found. There was no blood transfusion during the period of operation. The operation time ranged from 67 to 160 min (mean, 102.9 min). The amount of bleeding ranged from 40 to 120 ml (mean, 73.3 ml). All the patients were treated with nonheparin hemodialysis on the postoperative day 1. Regular hemodialysis was restarted on the postoperative day 6 or 7. Postoperative complications were observed in two cases, comprising of one case of acute left heart failure and one case of subcutaneous emphysema. All the patients recovered successfully and were discharged after operation in 7-12 d (mean, 8.1 d). The followup duration ranged from 5 to 70 months (mean, 35 months). All the patients survived and were still under hemodialysis. No recurrence or metastasis was found.ConclusionAs long as full preoperative preparation, meticulous perioperative management, individualized fluid infusion and timely hemodialysis, RLRN can be performed in maintenance hemodialysis patients with RCC safely and effectively.

参考文献/References:

[1]Nouh MA,Kuroda N,Yamashita M,et al.Renal cell carcinoma in patients with endstage renal disease:relationship between histological type and duration of dialysis.BJU Int,2010,105(5):620-627.
[2]Tsuzuki T,Iwata H,Murase Y,et al.Renal tumors in endstage renal disease:a comprehensive review.Int J Urol,2018,25(9):780-786.
[3]Neuzillet Y,Tillou X,Mathieu R,et al.Renal cell carcinoma (RCC) in patients with endstage renal disease exhibits many favourable clinical,pathologic,and outcome features compared with RCC in the general population.Eur Urol,2011,60(2):366-373.
[4]江雪艳,何毅,杨琦,等.尿毒症患者冠状动脉旁路移植术后的过渡性床旁连续性肾脏替代治疗观察.临床肾脏病杂志,2018,18(7):405-408.
[5]中国医师协会肾脏病医师分会血液透析充分性协作组.中国血液透析充分性临床实践指南.中华医学杂志,2015,95(34):2748-2753.
[6]王林辉,王梁,杨波,等.后腹腔镜下与开放根治性肾切除术治疗T1肾癌的疗效比较.中华泌尿外科杂志,2009,30(4):228-230.
[7]黄建林,安宇,廖勇,等.后腹腔镜保留肾单位手术治疗70岁以上老年局限性肾癌.中国微创外科杂志,2017,17(8):748-751.
[8]Taweemonkongsap T,Nualyong C,Amornvesukit T,et al.Retroperitoneoscopic nephrectomy in dialysis dependent patients and comparison with open surgery.J Med Assoc Thai,2008,91(11):1719-1725.
[9]Bird VG,Shields JM,Aziz M,et al.Transperitoneal laparoscopic radical nephrectomy for patients with dialysisdependent endstage renal disease: an analysis and comparison of perioperative outcome.Urology,2010,75(6):1335-1342.
[10]Iwamura M,Koh H,Soh S,et al.Retroperitoneoscopic radical nephrectomy by the posterior lumber approach for renalcell carcinoma associated with chronic renal failure.J Endourol,2001,15(7):729-734.
[11]Takei K,Yamasaki M,Abe S,et al.Laparoendoscopic singlesite nephrectomy for hemodialysis patients with dialysisrelated renal tumors.Minim Invasive Ther Allied Technol,2018,27(3):153-159.
[12]Khambati A,Fitzgerald MK,Perry KT,et al.Retroperitoneal laparoscopic radical nephrectomy allows continuation of peritoneal dialysis in patients with endstage renal disease.Perit Dial Int,2017,37(3):340-342.
[13]马南,姜兆磊,何毅,等.维持性血液透析合并瓣膜病患者的外科治疗.中国心血管病研究,2017,15(6):495-498.
[14]Breda A,Lucarelli G,RodriguezFaba O,et al.Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with endstage renal disease:a longterm comparative retrospective study with RCC diagnosed in the general population.World J Urol,2015,33(1):1-7.
[15]Chen K,Huang HH,Aydin H,et al.Renal cell carcinoma in patients with endstage renal disease is associated with more favourable histological features and prognosis.Scand J Urol,2015,49(3):200-204.
[16]Ito K,Takagi T,Kondo T,et al.Cystic local recurrence of renal cell carcinoma after laparoscopic radical nephrectomy in a hemodialysis patient.Int J Urol,2014,21(3):330-332.
[17]Omae K,Kondo T,Takagi T,et al.Surgical and oncologic outcomes of laparoscopic radical nephrectomy for nonmetastatic renal cancer in longterm dialysis patients.Ther Apher Dial,2017,21(1):31-37.

备注/Memo

备注/Memo:
基金项目：江西省重点研发计划项目（20171BBG70070）；江西省卫健委中医药计划（2018A378）**通讯作者，Email：zhuzwei@126.com
更新日期/Last Update: 2020-06-19